This content is from: Premium Hedge Funds Are Holding Their Breath on This Biopharma IPO Several prominent hedge funds disclosed sizable stakes in PepGen, which went public earlier this month. By Stephen Taub May 23, 2022
This content is from: Portfolio Why Investors Should Say No to Tech IPOs In the last decade, late-stage investments made before companies go public have generated the highest alpha. By Hannah Zhang May 10, 2022
This content is from: Portfolio New Valuation Data Show Private Companies Weathering the Downturn Better Than Public Peers Good and bad companies are being treated the same right now. Being able to discern between the two is where the opportunities are, says EQUIAM’s Ziad Makkawi. By Hannah Zhang May 19, 2022
This content is from: Portfolio There Are Plenty of Headwinds, but Don’t Expect Dealmaking to Come to a Screeching Halt Take-private transactions and low multiples in the tech sector are now attractive to dealmakers flush with cash. By Hannah Zhang May 31, 2022
This content is from: Portfolio Despite Market Rout, Hedge Funds Hold Steady With SPACs Marshall Wace, Saba Capital, and Millennium Management all add to their holdings amid the shakeout. By Michelle Celarier May 31, 2022
This content is from: Corner Office Declining Markets Aren’t DeterringSuMi Trust’s Expansion Into the U.S. — They May Even Help David Semaya is targeting $30 billion in investments, even though the states are “notoriously challenging for Japanese managers to do business in.” By Alicia McElhaney June 07, 2022
